Determination of risk and treatment of complications of prematurity
US7144707B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | May 28, 2003 |
| Grant date | Dec 5, 2006 |
| Priority date | — |
| Expiry date | May 28, 2023 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/368
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
In one aspect of the present invention there is provided a method for determining the risk of developing a complication of preterm birth in a patient born before 40 weeks of gestation or weighing 10% less than the average for the patient's gestational age. The method involves measuring serum IGF-I and/or IGF-I binding protein levels after birth of the patient to obtain an IGF-I or IGF-I binding protein level; and correlating said IGF-I or IGF-I binding protein level with an in utero baseline level of IGF-I or IGF-I binding protein based on gestational age matched mean levels in utero, wherein an IGF-I or IGF-I binding protein level below the mean gestational age in utero level indicates the patient is at an increased risk of developing a complication of preterm birth. The complications of preterm birth include retinopathy of prematurity, developmental delay, mental retardation, bronchopulmonary dysplasia, and intraventricular hemorrhage. Methods for treating/preventing complications of preterm birth are also provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.